Source:http://linkedlifedata.com/resource/pubmed/id/16518434
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2006-4-5
|
| pubmed:abstractText |
Haemopoietic stem cell therapy is an increasingly adopted procedure in the treatment of patients with malignant lymphoma. In this retrospective analysis, we evaluated 262 patients, 57 (22%) with Hodgkin's and 205 (78%) with non-Hodgkin's lymphomas (NHL), and 665 harvesting procedures in order to assess the impact of poor mobilization on survival and to determine the factors that may be predictive of CD34(+) poor mobilization. The mobilization chemotherapy regimens consisted of high-dose cyclophosphamide in 92 patients (35.1%) and a high-dose cytarabine-containing regimen (DHAP in 87 patients -(33.2%), MAD in 83 (31.7%)). The incidence of poor mobilizers (<2 x 10(6) CD34(+) cells/kg) was 17.9% overall, with a 10% of very poor mobilizers (< or = 1 x 10(6)/kg). Refractory disease status and chemotherapeutic load (>3 regimens) before mobilization played a negative role and were associated with poor mobilization. Survival analysis of all harvested patients showed an overall survival at 3 years of 71% in good mobilizers vs 33% in poor mobilizers (P=0.002). The event-free survival at 3 years was 23% in poor mobilizers and 58% in good mobilizers (P=0.04). We conclude that in NHL patients, poor mobilization status is predictive of survival.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
719-24
|
| pubmed:meshHeading |
pubmed-meshheading:16518434-Adult,
pubmed-meshheading:16518434-Antigens, CD34,
pubmed-meshheading:16518434-Antineoplastic Agents,
pubmed-meshheading:16518434-Disease-Free Survival,
pubmed-meshheading:16518434-Female,
pubmed-meshheading:16518434-Flow Cytometry,
pubmed-meshheading:16518434-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:16518434-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16518434-Humans,
pubmed-meshheading:16518434-Lymphoma,
pubmed-meshheading:16518434-Male,
pubmed-meshheading:16518434-Middle Aged,
pubmed-meshheading:16518434-Models, Statistical,
pubmed-meshheading:16518434-Multivariate Analysis,
pubmed-meshheading:16518434-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:16518434-Prognosis,
pubmed-meshheading:16518434-Retrospective Studies,
pubmed-meshheading:16518434-Stem Cells,
pubmed-meshheading:16518434-Time Factors,
pubmed-meshheading:16518434-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation.
|
| pubmed:affiliation |
Hematology Department, University of Bari, Bari, Italy.
|
| pubmed:publicationType |
Journal Article
|